Drug promotion: what we know, what we have yet to learn : reviews of materials in the WHO/HAI database on drug promotion

This document has been produced with the financial assistance of the European Community. The views expressed herein are those of the authors and can therefore in no way be taken to reflect the official opinion of the European Community. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization and Health Action International concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization and Health Action International in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization and Health Action International do not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use. The named authors alone are responsible for the views expressed in this publication. A sociologist and health services researcher, she works on pharmacy and medicine‐related issues. Her areas of interest include improving antibiotic use, evaluating pharmacy services, and the influence of ethnicity and socio‐ economic status on medicine use. She has written critical reviews of the research‐ based articles included in the WHO/HAI drug promotion database. Andrew Herxheimer taught clinical pharmacology and therapeutics at London University until 1991. He also founded the UK Drug and Therapeutics Bulletin in 1962 and edited it until 1992. Since then he has worked in the Cochrane Collaboration and is now Emeritus Fellow of the UK Cochrane Centre in Oxford. He is co‐founder of the charity DIPEx, a Database of Personal Experiences of illness (www.dipex.org). Chair of the International Society of Drug Bulletins until 1996, Andrew Herxheimer is interested in all aspects of providing professionals and the public with unbiased and clear information about the benefits and harms of therapeutic and diagnostic interventions. He has a continuing interest in all aspects of pharmaceutical promotion, and in the strategies that society, especially doctors and health services, can use to control or …

[1]  R Dajda.  Drug advertising and prescribing. , 1978, The Journal of the Royal College of General Practitioners.

[2]  L S Linn,et al.  Physicians' orientation toward the legitimacy of drug use and their preferred source of new drug information. , 1972, Social science & medicine.

[3]  T A Jeffers,et al.  Drug advertising in medical journals. , 1976, British journal of clinical pharmacology.

[4]  D. Moher,et al.  Redundancy, disaggregation, and the integrity of medical research , 1996, The Lancet.

[5]  P R Manning,et al.  How internists learned about cimetidine. , 1980, Annals of internal medicine.

[6]  Mark W. Speece,et al.  Effects of an educational intervention on residents’ knowledge and attitudes toward interactions with pharmaceutical representatives , 1997, Journal of General Internal Medicine.

[7]  M. Peyrot,et al.  Consumer awareness of prescription drug advertising , 1993 .

[8]  K. Dickersin,et al.  Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. , 1992, JAMA.

[9]  M. Cho,et al.  The Quality of Drug Studies Published in Symposium Proceedings , 1996, Annals of Internal Medicine.

[10]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[11]  C. Stocking,et al.  An Ethical Debate: Financial ties as part of informed consent to postmarketing research Attitudes of American doctors and patient , 1995 .

[12]  E. R. Peay,et al.  The role of commercial sources in the adoption of a new drug. , 1988, Social science & medicine.

[13]  C J Barnes,et al.  Student reactions to pharmaceutical promotion practices. , 1971, Northwest medicine.

[14]  Stephen A. Osiobe,et al.  Physicians' and Pharmacists' Drug Information Sources in Nigeria , 1988 .

[15]  L. White,et al.  Pharmaceutical representatives and emergency medicine residents: a national survey. , 1993, Annals of emergency medicine.

[16]  S B Soumerai,et al.  Coverage by the news media of the benefits and risks of medications. , 2000, The New England journal of medicine.

[17]  Paul Dieppe,et al.  Funding clinical research , 1999, The Lancet.

[18]  J Collier,et al.  Promotion by the British pharmaceutical industry, 1983-8: a critical analysis of self regulation. , 1990, BMJ.

[19]  M. Nettleman,et al.  Pharmaceutical branding of resident physicians. , 2001, JAMA.

[20]  M. Godwin,et al.  Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[21]  J R Hoffman,et al.  An innovative approach to educating medical students about pharmaceutical promotion. , 2001, Academic medicine : journal of the Association of American Medical Colleges.

[22]  L. Krupka,et al.  Prescription drug advertising: trends and implications. , 1985, Social science & medicine.

[23]  P. Rochon,et al.  A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. , 1994, Archives of internal medicine.

[24]  R. Blake,et al.  Patients' Attitudes About Gifts To Physicians From Pharmaceutical Companies , 1995, The Journal of the American Board of Family Medicine.

[25]  J M Westfall,et al.  Personal use of drug samples by physicians and office staff. , 1997, JAMA.

[26]  E. Howells,et al.  Factors linked to the prescribing of benzodiazepines by general practice principals and trainees. , 1992, Family practice.

[27]  Dilek Güldal,et al.  The Influences of Drug Companies' Advertising Programs on Physicians , 2000, International journal of health services : planning, administration, evaluation.

[28]  M. Koenigsberg,et al.  Sample medication dispensing in a residency practice. , 1992, The Journal of family practice.

[29]  J Lexchin,et al.  Interactions between physicians and the pharmaceutical industry: what does the literature say? , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[30]  A. J. Meadows,et al.  Use of drug information sources by hospital doctors , 1980 .

[31]  S. Krimsky,et al.  Academic-Corporate Ties in Biotechnology: A Quantitative Study , 1991, Science, technology & human values.

[32]  A F Shaughnessy,et al.  Sources of Influence on the Prescribing Practices of Residents in Family Medicine , 1991, DICP : the annals of pharmacotherapy.

[33]  A Lal,et al.  Critical evaluation of references in drug advertisements: an Indian experience. , 1996, The Journal of the Association of Physicians of India.

[34]  E. R. Peay,et al.  Patterns of preference for information sources in the adoption of new drugs by specialists. , 1990, Social science & medicine.

[35]  S S Iyer,et al.  What we have yet to learn. , 1974, Science.

[36]  J. H. Bennett,et al.  Teaching information mastery: evaluating information provided by pharmaceutical representatives. , 1995, Family medicine.

[37]  D Blumenthal,et al.  Participation of life-science faculty in research relationships with industry. , 1996, The New England journal of medicine.

[38]  Elaine D. Mackowiak,et al.  A Survey of Pharmacists' and Pharmacy Students' Attitudes Toward OTC Advertising , 1997 .

[39]  Thomas J. Maronick,et al.  A Review of Direct-to-Consumer (DTC) Advertising and Sales of Prescription Drugs: Does DTC Advertising Increase Sales and Market Share? , 2001 .

[40]  Deon Nel,et al.  Pharmaceutical Promotion Tools — Their Relative Importance , 1988 .

[41]  B. Crabtree,et al.  The value of pharmaceutical representative visits and medication samples in community-based family practices. , 2000, The Journal of family practice.

[42]  R S Kalish,et al.  Drug promotion. , 1995, The New England journal of medicine.

[43]  P P Lamy,et al.  Physicians' Knowledge of Prescribing for the Elderly , 1985, Journal of the American Geriatrics Society.

[44]  F Haayer,et al.  Rational prescribing and sources of information. , 1982, Social science & medicine.

[45]  M. Roth,et al.  Patterns in Direct-to-Consumer Prescription Drug Print Advertising and Their Public Policy Implications , 1996 .

[46]  P A Dieppe,et al.  Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint , 2000, Annals of the rheumatic diseases.

[47]  D. Elliott,et al.  The gift relationship between pharmaceutical companies and physicians: an exploratory survey of physicians , 1997, Journal of clinical pharmacy and therapeutics.

[48]  A Taylor,et al.  Violations of the international code of marketing of breast milk substitutes: prevalence in four countries , 1998, BMJ.

[49]  J. Orlowski,et al.  The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. , 1992, Chest.

[50]  G Tomson,et al.  'Codes' and practice: information in drug advertisements--an example from Sri Lanka. , 1990, Social science & medicine.

[51]  W P McKinney,et al.  Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. , 1990, Journal of the American Medical Association (JAMA).

[52]  M. Tramèr,et al.  Impact of covert duplicate publication on meta-analysis: a case study , 1997, BMJ.

[53]  M S Wilkes,et al.  Pharmaceutical Advertisements in Leading Medical Journals: Experts' Assessments , 1992, Annals of Internal Medicine.

[54]  Marjorie A. Bowman,et al.  The impact of drug company funding on the content of continuing medical education , 1986 .

[55]  D. Vinson,et al.  Medical students' attitudes toward pharmaceutical marketing: possibilities for change. , 1993, Family medicine.

[56]  D Blumenthal,et al.  Relationships between academic institutions and industry in the life sciences--an industry survey. , 1996, The New England journal of medicine.

[57]  N Freemantle,et al.  Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. , 2000, The British journal of psychiatry : the journal of mental science.

[58]  C B Anderson,et al.  A national survey of policies on disclosure of conflicts of interest in biomedical research. , 2000, The New England journal of medicine.

[59]  B. Hodges,et al.  Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[60]  A. Wertheimer,et al.  Sources of information and influence on new drug prescribing among physicians in an HMO. , 1979, Social science & medicine.

[61]  S. Wolfe,et al.  Prescriptions for Death: The Drugging of the Third World , 1983 .

[62]  F M Eckel,et al.  Community, hospital and clinical pharmacists and drug information centers as physician drug information sources. , 1978, American journal of hospital pharmacy.

[63]  R. Hatton,et al.  Physicians' Sources of Information about Teratogenic Effects of Drugs , 1982, Drug information journal.

[64]  J Lexchin,et al.  Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines? , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[65]  G. Oppenheim,et al.  The family physician's knowledge of the cost of prescribed drugs. , 1981, The Journal of family practice.

[66]  J Thomas.  National survey of recent changes in hospital policies on pharmaceutical sales representatives' activities. , 1989, American journal of hospital pharmacy.

[67]  M. Friedberg,et al.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology. , 1999, JAMA.

[68]  Anthony Thomson,et al.  Attitudes of general practitioners in New Zealand to pharmaceutical representatives. , 1994, The British journal of general practice : the journal of the Royal College of General Practitioners.

[69]  Tom Rockwell.  The Lifetime Experience With Prescription Drug Advertising Exposed To Consumers , 1986 .

[70]  R Hartley,et al.  Scientific versus commercial sources of influence on the prescribing behavior of physicians. , 1982, The American journal of medicine.

[71]  Z. Bhutta,et al.  A survey of paediatric prescribing and dispensing in Karachi. , 1990, JPMA. The Journal of the Pakistan Medical Association.

[72]  T R Sharpe,et al.  Government Regulation and the Believability of Prescription Drug Advertising , 1977, Drug intelligence & clinical pharmacy.

[73]  Mainous Ag rd,et al.  Patient perceptions of physician acceptance of gifts from the pharmaceutical industry. , 1995, Archives of family medicine.

[74]  E. Roughead,et al.  Self-Regulatory Codes of Conduct: Are They Effective in Controlling Pharmaceutical Representatives' Presentations to General Medical Practitioners? , 1998, International journal of health services : planning, administration, evaluation.

[75]  R A Giudici,et al.  Pharmacists' and physicians' attitudes toward pharmaceutical marketing practices. , 1994, American journal of hospital pharmacy.

[76]  D B Witzke,et al.  Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry. , 1993, Annals of emergency medicine.

[77]  L. Miller,et al.  Physician awareness of prescription drug costs: a missing element of drug advertising and promotion. , 1993, The Journal of family practice.

[78]  S. Kelcher,et al.  Structured approach to pharmaceutical representatives. Family medicine residency program. , 1998, Canadian family physician Medecin de famille canadien.

[79]  D Blumenthal,et al.  University-industry research relationships in biotechnology: implications for the university. , 1986, Science.

[80]  J. Ioannidis.  Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. , 1998, JAMA.

[81]  A S Detsky,et al.  Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. , 2001, JAMA.

[82]  P. Palmisano,et al.  Teaching drug promotion abuses to health profession students. , 1980, Journal of medical education.

[83]  C Bridges-Webb,et al.  Use of sources of therapeutic and prescribing information by general practitioners. , 1980, Australian family physician.

[84]  L Curry,et al.  Continuing medical education in Maritime Canada: the methods physicians use, would prefer and find most effective. , 1981, Canadian Medical Association journal.

[85]  C Saxton.  Overpromotion of drugs in international product package inserts. , 1983, Tropical doctor.

[86]  J. R. Williams,et al.  Changes in physicians' sources of pharmaceutical information: a review and analysis. , 1991, Journal of health care marketing.

[87]  M Silverman.  The Epidemiology of Drug Promotion , 1977, International journal of health services : planning, administration, evaluation.

[88]  P R Mansfield,et al.  Classifying improvements to drug marketing and justifications for claims of efficacy. , 1991, The International journal of risk & safety in medicine.

[89]  F Haaijer-Ruskamp.  Bad medicine: the prescription drug industry in the third world. , 1993, The International journal of risk & safety in medicine.

[90]  B Djulbegovic,et al.  Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[91]  P R Lee,et al.  Drug Promotion: The Third World Revisited , 1986, International journal of health services : planning, administration, evaluation.

[92]  G Eaton,et al.  Sources of drug information used by general practitioners. , 1976, The Journal of the Royal College of General Practitioners.

[93]  F. E. Russell.  Rattlesnakes: Klauber, L. M. Abridged Edition (McClung, K. H. Ed.), 339 pp. Berkeley: University of California Press (1982) , 1982 .

[94]  R. Simes,et al.  Publication bias: evidence of delayed publication in a cohort study of clinical research projects , 1997, BMJ.

[95]  J D McCue,et al.  Physicians' Opinions of the Accuracy, Accessibility, and Frequency of Use of Ten Sources of New Drug Information , 1986, Southern medical journal.

[96]  K R Evans,et al.  Physician acquisition of prescription drug information. , 1986, Journal of health care marketing.

[97]  C M Kunin.  Clinical investigators and the pharmaceutical industry. , 1978, Annals of internal medicine.

[98]  C. G. Suresh,et al.  Use of adenosine and effectiveness of pharmaceutical marketing , 1993, The Lancet.

[99]  P. Gøtzsche,et al.  Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. , 1999, JAMA.

[100]  E Dunn,et al.  Continuing medical education in ontario: a primary care perspective. , 1982, Canadian family physician Medecin de famille canadien.

[101]  Mary-Margaret Chren,et al.  Physiciansʼ Behavior and Their Interactions With Drug Companies: A Controlled Study of Physicians Who Requested Additions to a Hospital Drug Formulary , 1994 .

[102]  Lynda M. Maddox,et al.  Direct-to-Consumer Advertising of Prescription Drugs in Canada: Its Potential Effect on Patient-Physician Interaction , 1997 .

[103]  Leslie E. Wolf,et al.  Conflict-of-Interest Policies for Investigators in Clinical Trials , 2001 .

[104]  Charles Lipton.  Consumer Advertising and Pharmaceuticals: A Happy Marriage? , 1986 .

[105]  Carolyn M. Brown,et al.  Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[106]  Henry T. Stelfox,et al.  Conflict of interest in the debate over calcium-channel antagonists. , 1998, The New England journal of medicine.

[107]  J C Schommer,et al.  Rote learning after exposure to a direct-to-consumer television advertisement for a prescription drug. , 1998, Clinical therapeutics.

[108]  D. Mark,et al.  Policies regulating the activities of pharmaceutical representatives in residency programs. , 1992, The Journal of family practice.

[109]  A R Jadad,et al.  Systematic reviews and meta-analyses on treatment of asthma: critical evaluation , 2000, BMJ : British Medical Journal.

[110]  C. Gluud,et al.  Randomized clinical trials in Hepatology: Predictors of quality , 1999, Hepatology.

[111]  W. Michael Dickson,et al.  Direct to Consumer Prescription Drug Advertising: Consumer Attitudes and Physician Reaction , 1987 .

[112]  C Bain,et al.  PRESCRIPTION DRUG ADVERTISING: MEDICAL JOURNAL PRACTICES UNDER DIFFERENT TYPES OF CONTROL , 1979, The Medical journal of Australia.

[113]  R K Dikshit,et al.  Commercial source of drug information: comparison between the United Kingdom and India , 1994, BMJ.

[114]  K Lawrence,et al.  Pharmaceutical policies in Canadian family medicine training. Survey of residency programs. , 1997, Canadian family physician Medecin de famille canadien.

[115]  J. Cleary,et al.  Impact of Pharmaceutical Sales Representatives on Physician Antibiotic Prescribing , 1992, The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians.

[116]  T M Hayes,et al.  Continuing education for general practice and the role of the pharmaceutical industry. , 1990, The British journal of general practice : the journal of the Royal College of General Practitioners.

[117]  E. R. Stinson,et al.  Survey of health professionals' information habits and needs. Conducted through personal interviews. , 1980, JAMA.

[118]  N A Azimi,et al.  The effectiveness of cost-effectiveness analysis in containing costs , 1998, Journal of general internal medicine.

[119]  W P McKinney,et al.  Physicians, pharmaceutical sales representatives, and the cost of prescribing. , 1996, Archives of family medicine.

[120]  F M Hull,et al.  Sources of information about new drugs and attitudes towards drug prescribing: an international study of differences between primary care physicians. , 1987, Family practice.

[121]  P M Williamson,et al.  How general practitioners assess risks in using new drugs. , 1975, The Journal of the Royal College of General Practitioners.

[122]  Andreas M Pleil,et al.  Potential Outcomes Associated with Direct-to-Consumer Advertising of Prescription Drugs: Physicians' Perspectives , 1991 .

[123]  David Jarjoura,et al.  Practicing and resident physicians' views on pharmaceutical companies , 1996 .

[124]  S S Andaleeb,et al.  Physician attitudes toward pharmaceutical sales representatives , 1995, Health care management review.

[125]  L. Basara,et al.  The Impact of a Direct-to-Consumer Prescription Medication Advertising Campaign on New Prescription Volume , 1996 .

[126]  Richard P. Bagozzi,et al.  Factors Related to Physicians' Attitudes and Beliefs toward Drug Information Sources , 1994 .

[127]  A. Vitry,et al.  Drug marketing in French-speaking African countries. , 1993, Social science & medicine.

[128]  B Strickland-Hodge,et al.  Usage of Information Sources by General Practitioners1 , 1980, Journal of the Royal Society of Medicine.

[129]  M. Lipsky,et al.  The opinions and experiences of family physicians regarding direct-to-consumer advertising. , 1997, The Journal of family practice.

[130]  J J Anderson,et al.  Secular changes in published clinical trials of second-line agents in rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[131]  L Lasagna,et al.  A comparison of drug product information in four national compendia , 1983, Clinical pharmacology and therapeutics.

[132]  R Mapes,et al.  Aspects of British General Practitioners' Prescribing , 1977, Medical care.

[133]  J. Berlin,et al.  When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? , 1996, Academic medicine : journal of the Association of American Medical Colleges.

[134]  Alan Cantor,et al.  The uncertainty principle and industry-sponsored research , 2000, The Lancet.

[135]  M Bansinath,et al.  Brand versus generic prescribing: a perspective of the Indian cardiologists' viewpoint. , 1984, International journal of clinical pharmacology, therapy, and toxicology.

[136]  F R Rosendaal,et al.  Competing interests and controversy about third generation oral contraceptives. BMJ readers should know whose words they read. , 2000, BMJ.

[137]  B Strickland-Hodge,et al.  Identification and characterization of early and late prescribers in general practice. , 1982, Journal of the Royal Society of Medicine.

[138]  P. Easterbrook,et al.  Publication bias in clinical research , 1991, The Lancet.

[139]  D Blumenthal,et al.  Looking a gift horse in the mouth: corporate gifts supporting life sciences research. , 1998, JAMA.

[140]  L. Egede,et al.  Encounters with pharmaceutical sales representatives among practicing internists. , 1999, The American journal of medicine.

[141]  W G Crook.  Drug advertising. , 1969, The New England journal of medicine.

[142]  E. Hemminki,et al.  The Effect of a Doctor's Personal Characteristics and Working Circumstances on the Prescribing of Psychotropic Drugs , 1974, Medical care.

[143]  Bower Ad,et al.  Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. , 1987 .

[144]  D. Rennie,et al.  Influences on the Quality of Published Drug Studies , 1996, International Journal of Technology Assessment in Health Care.

[145]  R. C. Turner,et al.  Impact of pharmaceutical company representatives on internal medicine residency programs. A survey of residency program directors. , 1992, Archives of internal medicine.

[146]  Michael S. Wilkes,et al.  Policies, practices, and attitudes of north american medical journal editors , 1995, Journal of general internal medicine.

[147]  Barnes Cj,et al.  Student reactions to pharmaceutical promotion practices. , 1971 .

[148]  K. Kroenke,et al.  A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts , 1998, Journal of General Internal Medicine.

[149]  M S Wilkes,et al.  Direct-to-consumer prescription drug advertising: trends, impact, and implications. , 2000, Health affairs.

[150]  S W Birdwell,et al.  Perception of the role of medical-service representatives in hospitals. , 1990, American journal of hospital pharmacy.

[151]  J Thomas.  National survey of hospital policies on pharmaceutical sales representatives' activities. , 1987, American journal of hospital pharmacy.

[152]  N Murray-Lyon.  Communication in medicine: a study of how family doctors obtain information on recent advances in the treatment of rheumatic diseases , 1977, Medical education.

[153]  J P Gagnon,et al.  Effects of promotion on pharmaceutical demand. , 1985, Social science & medicine.

[154]  M. Dieperink,et al.  Industry-sponsored grand rounds and prescribing behavior. , 2001, JAMA.

[155]  M S Wilkes,et al.  Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses. , 1999, The Journal of family practice.

[156]  Lawrence D Egbert,et al.  Bad Medicine: The Prescription Drug Industry in the Third World , 1992 .

[157]  R S Stern,et al.  Drug promotion for an unlabeled indication--the case of topical tretinoin. , 1994, The New England journal of medicine.

[158]  A. Detsky,et al.  Relationships between authors of clinical practice guidelines and the pharmaceutical industry. , 2002, JAMA.

[159]  J Lexchin,et al.  Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[160]  R. Kravitz,et al.  Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey , 2002, BMJ : British Medical Journal.

[161]  J R Lion,et al.  Psychiatrists' opinions of psychotropic drug advertisements. , 1979, Social science & medicine. Medical psychology & medical sociology.

[162]  David Brinberg,et al.  Risk Disclosures in Televised Prescription Drug Advertising to Consumers , 1989 .

[163]  M Mandelkern.  Manufacturer support and outcome. , 1999, The Journal of clinical psychiatry.

[164]  P R Lee,et al.  The Drugging of the Third World , 1982, International journal of health services : planning, administration, evaluation.

[165]  G Eaton,et al.  General practitioners' views of information about drugs. , 1976, The Journal of the Royal College of General Practitioners.

[166]  G Tomson,et al.  Patients, doctors and their drugs , 1990, European Journal of Clinical Pharmacology.

[167]  L Lasagna,et al.  The Relationship between Physician Characteristics and Prescribing Appropriateness , 1972, Medical care.

[168]  Mayur Mohan Amonkar,et al.  Pharmacists' Attitudes Toward Product-Specific Television Advertising of Prescription Drugs , 1996 .

[169]  Eduardo Zárate Cárdenas,et al.  Prescribing habits of Peruvian physicians and factors influencing them. , 1995 .

[170]  Warren S. Sandberg,et al.  The effect of educational gifts from pharmaceutical firms on medical students' recall of company names or products , 1997 .

[171]  P Darzins,et al.  National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives. , 1996, Annals.

[172]  R F Moulds,et al.  Pharmaceutical advertisements in Australian medical publications —have they improved? , 1994, The Medical journal of Australia.

[173]  F M Haaijer-Ruskamp,et al.  Journalists and their sources of ideas and information on medicines. , 1994, Social science & medicine.

[174]  G D Anastasio,et al.  Pharmaceutical Marketing: Implications for Medical Residency Training , 1996, Pharmacotherapy.

[175]  D. Berings,et al.  The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice , 2004, European Journal of Clinical Pharmacology.

[176]  Gillian Pearce,et al.  Prescriber profile and postmarketing surveillance , 1993, The Lancet.

[177]  M D Rawlins,et al.  Review of company postmarketing surveillance studies. , 1992, BMJ.

[178]  L A Morris,et al.  Consumer attitudes about advertisements for medicinal drugs. , 1986, Social science & medicine.

[179]  V. A. Wade,et al.  DRUG COMPANIES' EVIDENCE TO JUSTIFY ADVERTISING , 1989, The Lancet.

[180]  C P Bradley,et al.  Prescribing new drugs: qualitative study of influences on consultants and general practitioners , 2001, BMJ : British Medical Journal.

[181]  Philip A. Titus,et al.  Physician attitudes toward pharmaceutical drug advertising , 1995 .

[182]  N G Osifo,et al.  Overpromotion of Drugs in International Product Package Inserts , 1983, Tropical doctor.

[183]  Mickey C. Smith,et al.  Direct-to-Consumer Advertising: Effects of Different Formats of Warning Information Disclosure on Cognitive Reactions of Adults , 1987 .

[184]  Marie A. Abate,et al.  Information Sources Utilized by Private Practice and University Physicians , 1989 .

[185]  A G Mainous,et al.  Attitudes of medical school faculty toward gifts from the pharmaceutical industry , 1992, Academic medicine : journal of the Association of American Medical Colleges.

[186]  Peter J. Jewesson,et al.  Activities of Pharmaceutical Industry Representatives at a Major Teaching Hospital , 1996 .

[187]  M. Ziegler,et al.  The accuracy of drug information from pharmaceutical sales representatives. , 1995, JAMA.

[188]  C M Bond,et al.  Change in the established prescribing habits of general practitioners: an analysis of initial prescriptions in general practice. , 1991, The British journal of general practice : the journal of the Royal College of General Practitioners.

[189]  R S Graham.  PRESCRIPTION DRUG ADVERTISING , 1991, The Canadian veterinary journal = La revue veterinaire canadienne.

[190]  Diederick E Grobbee,et al.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis , 2001, BMJ : British Medical Journal.

[191]  Füsun F. Gönül,et al.  Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior , 2001 .

[192]  M. Bowman,et al.  Changes in drug prescribing patterns related to commercial company funding of continuing medical education. , 1988, The Journal of continuing education in the health professions.

[193]  S. A. Osiobe,et al.  Sources of information for biomedical decision-making. , 1985, Methods of information in medicine.

[194]  E. R. Peay,et al.  Innovation in high risk drug therapy. , 1994, Social science & medicine.

[195]  W P McKinney,et al.  Pharmaceutical representatives in academic medical centers , 1990, Journal of General Internal Medicine.

[196]  F M Haaijer-Ruskamp,et al.  The use of drug information sources by physicians: development of a data-generating methodology. , 1996, Social science & medicine.

[197]  Paul Dieppe,et al.  Relation between agendas of the research community and the research consumer , 2000, The Lancet.

[198]  P Sandercock,et al.  Reports of randomized trials in acute stroke, 1955 to 1995. What proportions were commercially sponsored? , 1999, Stroke.

[199]  Bucci Kk,et al.  Involvement of pharmacy faculty in the development of policies for pharmaceutical sales representatives. , 1992 .

[200]  L Lasagna,et al.  Differential education concerning therapeutics and resultant physician prescribing patterns. , 1972, Journal of medical education.

[201]  D S Pathak,et al.  Health-related quality-of-life claims in prescription drug advertisements. , 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[202]  M. Chren,et al.  Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. , 1994, JAMA.

[203]  E. R. Peay,et al.  Differences among practitioners in patterns of preference for information sources in the adoption of new drugs. , 1984, Social science & medicine.

[204]  Robert H. Moser.  The Continuing Search: FDA Drug Information Survey , 1974 .

[205]  G L Burkett,et al.  Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. , 1987, The Journal of family practice.

[206]  Melissa S. Anderson,et al.  Withholding research results in academic life science. Evidence from a national survey of faculty. , 1997, JAMA.

[207]  J. Sacristán,et al.  Publication bias in health economic studies. , 1997, PharmacoEconomics.